Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,154 across all filing types
Latest filing 2026-05-11 Regulatory Filings
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Earnings Call to discuss the Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026.
Regulatory Filings Classification · 72% confidence The document is an announcement to stock exchanges and investors scheduling an earnings call to discuss audited financial results. It contains no actual financial data or highlights, nor is it the release of results itself (so it is not an ER), and it is not a transcript (CT). It is an event notice, thus falling under the catch‐all Regulatory Filings (RNS) category.
2026-05-11 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 82% confidence The document is an exchange filing notifying investors of a scheduled earnings call to discuss audited financial results, but it contains no actual financial data, highlights, or transcript. It is an invitation/notice rather than an earnings release (ER) or a call transcript (CT), and it does not attach or publish the report itself. Under the taxonomy, this type of miscellaneous regulatory announcement defaults to Regulatory Filings (RNS).
2026-05-11 English
Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2026 ,inter alia, to consider and approve This is to inform you ....
Regulatory Filings Classification · 85% confidence The document is a formal exchange filing under SEBI LODR Regulation 29 providing notice of a Board meeting to consider and approve audited results and recommend dividends. It does not itself contain financial statements nor announce a board change or dividend amount, nor is it the actual report. It is a general regulatory announcement (not a proxy, not a report publication), thus best classified as a Regulatory Filing (RNS).
2026-05-11 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2026-04-02 English
Trading Window
Regulatory Filings
2026-03-25 English
Giving guarantees/indemnity/ becoming a surety for third party
Regulatory Filings
2026-03-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.